# Gout Inflammation Time Programming: Molecular Clock from Crystal Triggering to Tissue Remodeling

**Authors:** Xin Chen, Chunyuan Zhang, Hanwen Zheng, Qingping Shi, Beiyan Chen, Jieru Han

PMC · DOI: 10.3390/ijms27031523 · International Journal of Molecular Sciences · 2026-02-04

## TL;DR

This paper introduces a new model for understanding gout inflammation as a timed process with distinct phases and potential for targeted treatment.

## Contribution

The paper presents a novel temporal framework for gout inflammation with stage-specific therapeutic strategies.

## Key findings

- Gout inflammation progresses through three timed phases: acute, adaptation, and chronic tissue injury.
- Each phase offers distinct therapeutic windows for precision interventions.
- Cutting-edge technologies like digital twin joint models can enhance spatiotemporal treatment precision.

## Abstract

This review introduces and elaborates a novel temporal paradigm, the “Gout Inflammation Time Programming” model, conceptualized through the Gout-STAT™ framework. This model redefines gout inflammation as a dynamic continuum progressing through three precisely timed phases: an acute Perception phase (0–24 h) initiated by monosodium urate (MSU) crystal recognition, triggering the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome and neutrophil-driven burst; a critical Adaptation phase (24–72 h) where outcomes are determined by immunometabolic reprogramming of macrophages and synovial fibroblasts; and a chronic Tissue Injury phase (>72 h) driven by epigenetic memory, leading to irreversible osteoarticular destruction. Deciphering this programmed timeline reveals distinct therapeutic windows. We propose a shift towards stage-specific precision interventions, targeting upstream triggers (e.g., mitochondrial reactive oxygen species(ROS), neutrophil extracellular trap formation (NETosis)) in the acute phase, correcting metabolic checkpoints (e.g., succinate accumulation, impaired autophagy) during adaptation, and employing tissue-protective strategies (e.g., epigenetic modulators) in the chronic phase. Furthermore, we highlight the pivotal role of cutting-edge translational technologies, such as intelligent drug delivery systems and digital twin joint models, in achieving spatiotemporal precision. Understanding this intrinsic molecular clock is fundamental for advancing gout management from reactive treatment to a predictive, preventive, and personalized 4P medicine approach.

## Linked entities

- **Chemicals:** monosodium urate (PubChem CID 23690430), succinate (PubChem CID 160419)
- **Diseases:** gout (MONDO:0005393)

## Full-text entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}
- **Diseases:** osteoarticular destruction (MESH:D014394), Tissue Injury (MESH:D017695), Inflammation (MESH:D007249), Gout (MESH:D006073)
- **Chemicals:** MSU (MESH:D014527), 4P (-), succinate (MESH:D019802), ROS (MESH:D017382)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12897657/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12897657/full.md

## References

145 references — full list in the complete paper: https://tomesphere.com/paper/PMC12897657/full.md

---
Source: https://tomesphere.com/paper/PMC12897657